<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227344</url>
  </required_header>
  <id_info>
    <org_study_id>CACAF2</org_study_id>
    <nct_id>NCT00227344</nct_id>
  </id_info>
  <brief_title>CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation</brief_title>
  <acronym>CACAF-2</acronym>
  <official_title>Catheter Ablation for Cure of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster EMEA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective multicenter randomized study is to establish the
      effectiveness of treatment of persistent atrial fibrillation by encircling the pulmonary
      veins with radiofrequency (RF) ablation and creating additional lines of block with the aid
      of the NAVISTAR® THERMOCOOL® catheter in conjunction with the CARTO™ EP Navigation System.
      Effectiveness will be determined by comparing the chronic success of ablation therapy versus
      antiarrhythmic drug therapy, defined as the absence of persistent tachyarrhythmias during the
      first 24 months after a run-in phase of 2 months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study prematurely terminated due to randomization imbalance.
  </why_stopped>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Absence of Persistent Atrial Tachyarrhythmias Relapse During the First 24 Months After the run-in Phase (2 Months).</measure>
    <time_frame>within first 24 months after a 2-month run-in phase</time_frame>
    <description>Persistent atrial tachyarrhythmia is defined as lasting 7 or more days per two consecutive transtelephonic monitoring or electrocardiogram recordings (obtained at least one week apart) with no cardioversions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Total Absence of Any Documented Atrial Tachyarrhythmias Lasting Longer Than 30 Seconds During the First 24 Months After the run-in Phase (2 Months)</measure>
    <time_frame>within first 24 months after a 2-month run-in phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Procedural Success</measure>
    <time_frame>The day of the procedure</time_frame>
    <description>Procedural success was determined on the day of the procedure (Day 0) and was based on responses to the following:
&quot;Has a validation of the lesions been performed by taking 3 points inside each circular lesion?&quot;
&quot;If YES to #1, did you observe that none of them exceed 0.1 mV?&quot;
&quot;Did you observe any adverse event during the procedure?&quot;
If the answers to (1 ) and (2 ) were YES and (3) was NO, then the procedure was determined a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Recurrence of Any Tachyarrhythmias Lasting 30 or More Seconds After the Run in Phase</measure>
    <time_frame>day 61 through 790</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Clinical Success (Subjects Taking AADs That Remain Free From Any Tachyarrhythmias) in Association With Antiarrhythmic Drugs</measure>
    <time_frame>at 26 months and at each patients last follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>at 14, 26 and 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-economics Parameters (Days of Hospitalization)</measure>
    <time_frame>at 26 months and at each patients last follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Normal Sinus Rhythm at the Last Follow-up Visit Measured by ECG and 24-hour Holter Monitor</measure>
    <time_frame>at each patients last follow-up visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiarrhythmic drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF ablation</intervention_name>
    <description>Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drugs</intervention_name>
    <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years

          -  Written informed consent

          -  One documented relapse of atrial fibrillation (AF) during antiarrhythmic drug therapy
             after an electrical cardioversion

        Exclusion Criteria:

          -  Permanent atrial fibrillation

          -  Patients who had tried &gt;1 antiarrhythmic drug (Class I or Class III).

          -  AF was the sole rhythm for &gt;6 months before the enrollment.

          -  Previous ablation for AF.

          -  AF is deemed secondary to a transient or correctable abnormality including electrolyte
             imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy.

          -  Patients who have fibrillation episodes triggered by another uniform arrhythmia (eg,
             atrial flutter or atrial tachycardia).

          -  Patients with intra-atrial thrombus, tumor, or another abnormality that precludes
             catheter introduction.

          -  Patients with Wolf-Parkinson-White syndrome.

          -  Patients awaiting cardiac transplantation.

          -  Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-III-IV or
             ejection fraction (EF) &lt;40%.

          -  Patients with unstable angina or acute myocardial infarction within 3 months.

          -  Patients with cardiac revascularization or other cardiac surgery within 6 months.

          -  Patients with heart disease in which corrective surgery is anticipated.

          -  Patients in whom appropriate vascular access is precluded.

          -  Pregnant women.

          -  A separate requirement for antiarrhythmic drug treatment, which will require an
             antiarrhythmic drug not previously tried for AF suppression.

          -  Prior atrial surgery.

          -  Contraindication to treatment with warfarin or other bleeding diathesis.

          -  Renal failure requiring dialysis.

          -  Hepatic failure.

          -  Participant in investigational clinical or device trial.

          -  Unwilling or unable to give informed consent.

          -  Inaccessible for follow-up.

          -  Psychological problem that might limit compliance.

          -  Active abuse of alcohol or other drugs which may be causative of AF.

          -  An implanted device (pacemaker or cardioverter-defibrillator).

          -  Left atrial diameter (anteroposterior) &gt;50 mm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Bertaglia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ULSS n.13, Mirano (VE), Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Stabile, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Casa di Cura San Michele, Maddaloni, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oulu Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. ULSS no. 15 Alta Padovana</name>
      <address>
        <city>Camposampiero (VE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL no. 6</name>
      <address>
        <city>Cirie (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Villa Maria Cecilia</name>
      <address>
        <city>Cotignola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. di Ferrara- Arcispedale Sant'Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura San Michele</name>
      <address>
        <city>Maddaloni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS no. 13</name>
      <address>
        <city>Mirano (VE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Eugenio</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Provinciale per I Serv. Sanit.</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS no. 10</name>
      <address>
        <city>Treviso (VE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <results_first_submitted>May 27, 2014</results_first_submitted>
  <results_first_submitted_qc>January 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One hundred twenty-nine (129) subjects were enrolled in the study at the time of termination. Ten of 13 study sites were in Italy, thus the majority of subjects were recruited from Italian sites. The sponsor's decision at study termination was to report primary and secondary endpoints for which meaningful data analysis was possible.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Catheter Ablation</title>
          <description>Catheter Ablation</description>
        </group>
        <group group_id="P2">
          <title>Antiarrhythmic Drug Treatment</title>
          <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>study terminated early</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Catheter Ablation</title>
          <description>Catheter Ablation</description>
        </group>
        <group group_id="B2">
          <title>Antiarrhythmic Drug Treatment</title>
          <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="8.9"/>
                    <measurement group_id="B2" value="64.3" spread="4.7"/>
                    <measurement group_id="B3" value="59.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Absence of Persistent Atrial Tachyarrhythmias Relapse During the First 24 Months After the run-in Phase (2 Months).</title>
        <description>Persistent atrial tachyarrhythmia is defined as lasting 7 or more days per two consecutive transtelephonic monitoring or electrocardiogram recordings (obtained at least one week apart) with no cardioversions.</description>
        <time_frame>within first 24 months after a 2-month run-in phase</time_frame>
        <population>Intention to treat (ITT) analysis includes subjects with available transtelephonic monitoring data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absence of Persistent Atrial Tachyarrhythmias Relapse During the First 24 Months After the run-in Phase (2 Months).</title>
          <description>Persistent atrial tachyarrhythmia is defined as lasting 7 or more days per two consecutive transtelephonic monitoring or electrocardiogram recordings (obtained at least one week apart) with no cardioversions.</description>
          <population>Intention to treat (ITT) analysis includes subjects with available transtelephonic monitoring data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Total Absence of Any Documented Atrial Tachyarrhythmias Lasting Longer Than 30 Seconds During the First 24 Months After the run-in Phase (2 Months)</title>
        <time_frame>within first 24 months after a 2-month run-in phase</time_frame>
        <population>Intention to treat (ITT) analysis includes subjects with available transtelephonic monitoring data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Total Absence of Any Documented Atrial Tachyarrhythmias Lasting Longer Than 30 Seconds During the First 24 Months After the run-in Phase (2 Months)</title>
          <population>Intention to treat (ITT) analysis includes subjects with available transtelephonic monitoring data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Procedural Success</title>
        <description>Procedural success was determined on the day of the procedure (Day 0) and was based on responses to the following:
“Has a validation of the lesions been performed by taking 3 points inside each circular lesion?”
“If YES to #1, did you observe that none of them exceed 0.1 mV?”
“Did you observe any adverse event during the procedure?”
If the answers to (1 ) and (2 ) were YES and (3) was NO, then the procedure was determined a success.</description>
        <time_frame>The day of the procedure</time_frame>
        <population>Procedural success was only calculated for the catheter ablation group. Intention to Treat (ITT) analysis of procedural success for the catheter ablation group was performed using available data. The &quot;0&quot; below the Antiarrhythmic Drug treatment group represents &quot;not available.&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Procedural Success</title>
          <description>Procedural success was determined on the day of the procedure (Day 0) and was based on responses to the following:
“Has a validation of the lesions been performed by taking 3 points inside each circular lesion?”
“If YES to #1, did you observe that none of them exceed 0.1 mV?”
“Did you observe any adverse event during the procedure?”
If the answers to (1 ) and (2 ) were YES and (3) was NO, then the procedure was determined a success.</description>
          <population>Procedural success was only calculated for the catheter ablation group. Intention to Treat (ITT) analysis of procedural success for the catheter ablation group was performed using available data. The &quot;0&quot; below the Antiarrhythmic Drug treatment group represents &quot;not available.&quot;</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Recurrence of Any Tachyarrhythmias Lasting 30 or More Seconds After the Run in Phase</title>
        <time_frame>day 61 through 790</time_frame>
        <population>Intention to treat (ITT) analysis includes subjects with available transtelephonic monitoring data. The upper bound of the confidence interval for the drug treatment group could not be calculated because of the high censoring rate. Therefore, &quot;NA&quot; is more appropriate in place of the maximum duration of follow-up (790.0) as the upper bound.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Recurrence of Any Tachyarrhythmias Lasting 30 or More Seconds After the Run in Phase</title>
          <population>Intention to treat (ITT) analysis includes subjects with available transtelephonic monitoring data. The upper bound of the confidence interval for the drug treatment group could not be calculated because of the high censoring rate. Therefore, &quot;NA&quot; is more appropriate in place of the maximum duration of follow-up (790.0) as the upper bound.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.0" lower_limit="133.0" upper_limit="436.0"/>
                    <measurement group_id="O2" value="328.0" lower_limit="165.0">The upper bound of the confidence interval for the drug treatment group could not be calculated because of the high censoring rate. Therefore, &quot;NA&quot; is more appropriate in place of the maximum duration of follow-up (790.0) as the upper bound.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Clinical Success (Subjects Taking AADs That Remain Free From Any Tachyarrhythmias) in Association With Antiarrhythmic Drugs</title>
        <time_frame>at 26 months and at each patients last follow-up visit</time_frame>
        <population>Study termination due to randomization imbalance. Data not analyzed since enrollment limited and therefore insufficient data to identify meaningful differences and draw significant conclusions. The &quot;0&quot; below represents &quot;not available.&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Clinical Success (Subjects Taking AADs That Remain Free From Any Tachyarrhythmias) in Association With Antiarrhythmic Drugs</title>
          <population>Study termination due to randomization imbalance. Data not analyzed since enrollment limited and therefore insufficient data to identify meaningful differences and draw significant conclusions. The &quot;0&quot; below represents &quot;not available.&quot;</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <time_frame>at 14, 26 and 38 months</time_frame>
        <population>Study termination due to randomization imbalance. Data not analyzed since enrollment limited and therefore insufficient data to identify meaningful differences and draw significant conclusions. The &quot;0&quot; below represents &quot;not available.&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <population>Study termination due to randomization imbalance. Data not analyzed since enrollment limited and therefore insufficient data to identify meaningful differences and draw significant conclusions. The &quot;0&quot; below represents &quot;not available.&quot;</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-economics Parameters (Days of Hospitalization)</title>
        <time_frame>at 26 months and at each patients last follow-up visit</time_frame>
        <population>Data not analyzed due to study termination - insufficient data to identify meaningful differences and draw significant conclusions.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Health-economics Parameters (Days of Hospitalization)</title>
          <population>Data not analyzed due to study termination - insufficient data to identify meaningful differences and draw significant conclusions.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Normal Sinus Rhythm at the Last Follow-up Visit Measured by ECG and 24-hour Holter Monitor</title>
        <time_frame>at each patients last follow-up visit</time_frame>
        <population>Intention to Treat (ITT)analysis of sinus rhythm was performed for subjects with available Holter Monitor data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>Catheter Ablation</description>
          </group>
          <group group_id="O2">
            <title>Antiarrhythmic Drug Treatment</title>
            <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Normal Sinus Rhythm at the Last Follow-up Visit Measured by ECG and 24-hour Holter Monitor</title>
          <population>Intention to Treat (ITT)analysis of sinus rhythm was performed for subjects with available Holter Monitor data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6"/>
                    <measurement group_id="O2" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Catheter Ablation</title>
          <description>Catheter Ablation</description>
        </group>
        <group group_id="E2">
          <title>Antiarrhythmic Drug Treatment</title>
          <description>Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>low hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>lipotimia and hyperkaliemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>coronary angiography</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>all types of atrial flutter including, but not limited to atypical and left atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>worsening ventricular function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>sinusal arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>torsade de pointes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>silent ischemic heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>sinus pause</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>diabetes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>reduced visual acuity secondary to cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>colon polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>cardiac tamponade</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>cerebral aneurism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>right knee trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>brain injury secondary to facial trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>artero-venious fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>increased tumor size</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>genital-urinary area neoplastic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>tremens</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>nasal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ablate and pace procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>pacemaker implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>atrioventricular node ablation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>carotid atrery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>corneal deposit of amiodarone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI’s rights to discuss, present or publish trial results after the trial is completed. Please contact Biosense Webster, Inc. for additional information.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early due to randomization imbalance. The relatively small number of subjects enrolled limited the amount of data available for analysis. Because the study did not reach its targeted enrollment, the study is underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pat Ticknor, Clinical Operations</name_or_title>
      <organization>Biosense Webster, Inc.</organization>
      <phone>909-839-8500</phone>
      <email>PTicknor@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

